Recent trial failures have called into question the central role of α-synuclein in Parkinson’s disease pathology. Although many continue to target α-synuclein aggregates in the brain, others are paying attention to the endolysosomal pathway, mitochondria and even glucose metabolism.
This is a preview of subscription content, log in via an institution to check access.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Johnson, B. Parkinson’s disease drug hunters think outside the α-synuclein box. Nat Biotechnol 40, 1705–1707 (2022). https://doi.org/10.1038/s41587-022-01610-w
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41587-022-01610-w
- Springer Nature America, Inc.